Can you reach your doctor after you start
The manufacturer Novo Nordisk limited the supply (in May 2023) of lower doses of semaglutide to meet the needs of patients already taking semaglutide
That means GLP-1 coverage paired with the right clinical model, physician oversight, nutrition support, behavioral engagement, AI & Intelligence for personalization, data-driven targeting, and a long-term plan for sustainable health improvement
Conclusion While both compounded semaglutide and Ozempic aim to manage type 2 diabetes and support weight loss, they differ significantly in regulatory approval, formulation consistency, cost, and availability
Our endocrinology-informed approach focuses on addressing the root causes of insulin resistance while supporting your bodys natural metabolic processes